Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036690 (
sepsis
)
59,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Daily prophylactic application of either 1.0%
silver
sulfadiazine cream or 0.1% gentamicin cream was compared for effectiveness in preventing bacterial colonization of burn wounds and
sepsis
. Pseudomonas aeruginosa colonized the wounds of 37% of the 38 patients treated with
silver
sulfadiazine and 30% of the 33 patients treated with gentamicin; gentamicin-resistant P. aeruginosa colonized the wounds of 21% of the patients treated with gentamicin. Staphylococcus aureus colonization occurred in 55% of the patients treated with
silver
sulfadiazine, whereas colonization with Candida species occurred in 58% of the patients treated with gentamicin. Although gentamicin-resistant organisms caused no deaths their repeated appearance resulted in discontinuation of prophylaxiz with gentamicin cream. The next year P. aeruginosa strains resistant to gentamicin were isolated from burn wounds of only two patients who had not previously received parenteral therapy with gentamicin or tobramycin. Gentamicin cream should be reserved for treating patients with wounds infected by gentamicin-sensitive P. aeruginosa and those allergic to sulfa drugs. For most patients with burn wounds
silver
sulfadiazine is safe and effective as an antibacterial agent for topical prophylaxis.
...
PMID:Comparison of silver sulfadiazine and gentamicin for topical prophylaxis against burn wound sepsis. 9 23
The large mass of devitalized tissue that comprises the burn eschar is gradually becoming recognized as the principal source of complications in the burn patient. Clinical observations suggest that the topical agent
silver
sulfadiazine does not penetrate the eschar sufficiently to prevent bacterial infection from becoming established in the deeper levels of the wound but does penetrate to a depth of approximately 1.5 mm in bactericidal concentrations. A new technique that takes advantage of this fact, early laminar excision, has been developed at the Children's Hospital of Michigan Burn Center. The eschar is excised layer by layer with the electric dermatome under general anesthesia within the first 72 hr post burn, and the thickness of the devitalized tissue is reduced to a remnant of less than 1 mm. This is less than the depth to which
silver
sulfadiazine is capable of penetrating in bactericidal concentrations, and greatly enhanced control of burn wound
sepsis
is achieved. Early laminar excision of the eschar, combined with
silver
sulfadiazine dressings, aggressive resurfacing of the wound, and increased emphasis on nutrition, is an approach to management of the victims of thermal trauma that should significantly improve survival in patients with burn injuries greater than 60% body surface area.
...
PMID:Early laminar excision: improved control of burn wound sepsis by partial dermatome debridement. 36 94
Three groups of extensive burn patients of the surgical intensive care unit (ICU) have been compared: Group I: twenty patients, who were treated locally without
silver
sulfadiazinate (1968-1970); Group II: the twenty first patients topically treated with
silver
sulfadiazinate (1970-1972); Group III: twenty similarly treated patients, with
silver
sulfadiazinate, six years later (1976-1977). The groups are statistically comparable. All bacteriological samples were computerized; the chi-square method was used for statistical analysis of the data. The main conclusions are: (A)
Silver
sulfadiazinate treatment reduced Pseudomonas aeruginosa and Proteus
sepsis
. No change in Coliform bacilli
sepsis
was observed. After six years, a rise in Klebsiella sepsis and Candida sepsis was noted. (B) A quantitative estimate of infections in each group was made by measuring the percentage of positive samples, taking into account the five above-mentioned strains. In the beginning,
silver
sulfadiazinate reduced quantitative
sepsis
, but this benefit decreased after six years; the same evolution was demonstrated for positive blood bacteriology; severe septicaemia showed a parallel pattern.
...
PMID:A ten-year retrospective study of sepsis in severely burned patients treated with or without silver sulfadiazinate. 45 85
Enterobacter cloacae
sepsis
was found in 15 burn center patients in 1976, of whom 13 died. Nine of the deaths occurred in the first 60 days. The Burn Center isolates were resistant to
silver
sulfadiazine (AgSD) in agar cup-plate tests and confirmed by tube dilution tests. Hospital, non-burn isolates of E. cloacae were sensitive to AgSD. All E. cloacae isolates were sensitive to mafenide acetate (MA) in the agar cup-plate tests, but this was not confirmed by the tube dilution tests. The agar cup-plate susceptibility test is a simple, rapid and effective technique for determining resistant and sensitive isolates of E. cloacae. Patients who were changed from AgSD to MA because of resistant E. cloacae infection did not have improved survival. An animal study showed that AgSD was ineffective against this strain of E. cloacae and that MA was more effective than AgSD when applied 24 hr postburn but neither were effective at 48 hr postburn. MA was bacteriostatic but not bactericidal with this E. cloacae strain.
...
PMID:Resistant Enterobacter cloacae in a burn center: the ineffectiveness of silver sulfadiazine. 66 Jun 84
Analysis of 300 consecutive hospitalized children with burns. To prevent infection, patients are given a bath with chlorhexidine (0.03%) every day and their burns covered by
silver
sulfadiazine (1%) and occlusive dressings. In 5.3% of the children positive swabs were obtained during hospitalization and in only 2.3% on several occasions. No case of
septicemia
could be documented.
...
PMID:[Anti-infections prophylaxis of infantile burns (author's transl)]. 70 74
The control of
sepsis
in burn wounds has long been the unrealized ideal of surgeons. This has been most nearly achieved by topical applications of
silver
sulphadiazine and chlorhexidine cream. An account is given of its probable mode of action and the method of application, together with an anlysis of the bacteriological results in 809 patients from December, 1969, to March, 1974.
...
PMID:Topical use of silver sulphadiazine and chlorhexidine in the prevention of infection in thermal injuries. 80 68
Zinc sulfadiazine is a new compound which is effective in vitro and in vivo against Pseudomonas aeruginosa infections in burned mice and rats. It contains an important body constituent, zinc, and appears to expedite wound healing, diminish weight loss after infected burns and improve food intake. Like
silver
sulfadiazine, it prevents the postburn changes in plasma proteins. After topical application, the uptake of the radioactively labeled zinc is significant in the zone of injury and negligible in organs and body fluids. The binding to deoxyribonucleic acid by zinc is similar to, but less than, that by
silver
. The data indicate that zinc sulfadiazine may be a valuable addition to the therapeutic armamentarium for the control of burn wound
sepsis
.
...
PMID:Zinc sulfadiazine for topical therapy of pseudomonas infection in burns. 81 19
Among the main aspects to be considered when treating burns, the problem of infection control remains unsolved. Considerable financial resources are needed to prevent the transmission of organisms. To justify such investments in buildings and antiseptic measures, an extensive epidemiological hospital study was carried out from 1970 to 1974, involving 930 patients, and more than 25,000 wound biopsies as well as 10,000 contact cultures and environmental swabs. Bacteria from the environment of severly burned patients were counted every week. Serotyping was used for a specialized study of Pseudomonas aeruginosa. In 200 patients wound organisms were counted. The most important organisms were: Streptococcaceae (pyogenic streptococci, less frequently faecal and salivary streptococci). Pseudomonadaceae, Enterobacteriaceae, and Micrococcaceae (especially Micrococcus aureus). Povidon iodine, gentamicin and
silver
sulfadiazine were used for local disinfection. Antibiotics used were gentamicin, carbenicillin and polymyxin. Whereas from 1970 to 1972 P. aeruginosa was the predominant organism found in wounds, other gram-positive organisms increased from 1972 on. Wounds were colonized mainly in the course of the first two weeks of treatment. Special studies regarding P. aeruginosa revealed a predominance of serotypes 5 and 13 between 1970 and 1973, whereas types brought into the hospital were dominant from 1973 on. An analysis of furniture and equipment, water faucets and drains showed that Pseudomonas strains found in the water did not coincide with those found in wounds. Therefore, a contamination from this source seems unlikely. Strains found on furniture and equipment, however, also appeared in the wound flora. When the therapeutic routine was changed (to prevent patients passing through common treatment areas such as bathrooms and dressing areas) hospital organisms 5 and 13 could be eliminated almost completely. Thus, it is possible to achieve a considerable reduction in the rate of cross-infection among patients by, for instance, excluding common treatment areas from the therapy programme. Nevertheless, in the majority of cases wounds will still be colonized, in particular by bacteria that were already in the anal region or on the skin before the patient was injured. For this reason, the elimination of such organisms by topical bactericidal agents constitutes an an important factor in efforts to reduce the rate of septicaemic complications. In view of the persisting high mortality due to generalized infections this therapeutic aspect must also be exploited thoroughly in the future. Although in comparative studies of topical therapy using povidon iodine,
silver
sulfadiazine and gentamicin, organisms did appear in the course of the first two weeks; in the case of the PVP-I the colonization never reached 10(5) organisms per cm2, i.e. the danger threshold for generalized
sepsis
. There was no evidence of a correlation between number of organisms and depth of burns.
...
PMID:[Asepsis and antisepsis in the treatment of burn patients (author's transl)]. 85 28
We describe our experimental studies of a powder formulated to treat serious burn wounds on-the-scene. The wound powder comprises two parts
silver
-citro-allantoinate, two parts zinc allantoinate and 96 parts pure allantoin. The back skin of 62 rats was shaved and exposed to actively boiling water for ten seconds, resulting in third degree burns of 20% of the total body surface. Immediately, 1 ml of a culture containing 2 X 10(8) Pseudomonas aeruginosa was applied to the burn. The animals were isolated. Of the 30 control rats, six were powdered with allantoin only. Thirty-two rats were dusted with the
silver
-zinc-allantoin powder within 15 minutes of burning. Cultures were taken at 48 hour intervals. Eighty-seven percent of the control animals died an average of six days postburn. In the treated animals, the mortality was 15%. A mean of 27% of the applied
silver
(0.35 gm) became incorporated in the eschar. In all control rats,
sepsis
was detected under the eschar. In treated animals, bacterial concentration fell from an initial average of 5 X 10(4) at 4 hours postburn to 6 X 10(2) at 96 hours.
...
PMID:The use of silver-zinc-allantoin powder for the prehospital treatment of burns. 87 Jul 34
Silver sulfadiazine (
Silvadene
, U.S.; Flamazine, U.K.; Flammazine, N.; Sulplata, S.A.) is the newest topical antimicrobial agent available following worldwide clinical trials. Good control of infection is achieved without pain or other demonstrable side effects, using either dressings or the exposure technic. Many burned areas kept free of infection heal without grafting. Where necessary, early preparation for and good take of grafts has been attained by utilizing this new therapeutic agent. Markedly reduced mortality from burn wound
sepsis
has generally been observed.
...
PMID:Silver sulfadiazine for control of burn wound infections. 109 31
1
2
3
4
5
6
7
8
9
10
Next >>